Finance

Lists
Outlook: 37.5% bullish·3.1% bearish
Go to analysis
AXSM:NASDAQ
Axsome Therapeutics Inc
$132.37
+1.98%
(+2.57) 1D
Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AXSM...
Open
$130.46
High
$133.78
Low
$130.00
Mkt. cap
6.96B
Avg. vol.
1.07M
Volume
0.00
52-wk high
$260.19
52-wk low
$123.00
EPS
-$3.06
Beta
0.86
Shares outstanding
52.60M
No. of employees
1K
Open
$130.46
High
$133.78
Low
$130.00
Mkt. cap
6.96B
Avg. vol.
1.07M
Volume
0.00
52-wk high
$260.19
52-wk low
$123.00
EPS
-$3.06
Beta
0.86
Shares outstanding
52.60M
No. of employees
1K
News stories
From web sources and news partners
About Axsome Therapeutics Inc
CEOHerriot Tabuteau
Employees1.39K
Founded2012
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteaxsome.com
Analyst ratings
Based on 20 analysts giving stock ratings to AXSM in the past 3 months
Strong buy
Buy
19
Hold
1
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for AXSM in the last 3 months.
Highest
Current $132.37
$310.00 (+134.19%)
Average
$260.42 (+96.74%)
Lowest
$135.00 (+1.99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$272.00
+105.5%
11/04/2026
David Hoang
Deutsche Bank
Buy
Maintained
$245.00
+85.1%
11/03/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$300.00
+126.6%
11/03/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
$272.00
+105.5%
11/02/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$256.00
+93.4%
11/03/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$250.00
+88.9%
11/03/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$220.00
+66.2%
11/03/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$249.00
+88.1%
11/03/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$264.00
+99.4%
11/02/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$273.00
+106.2%
11/02/2026
Ashwani Verma
UBS
Buy
Reiterated
$239.00
+80.6%
11/03/2026
Malcolm Hoffman
BMO Capital
Buy
Maintained
$310.00
+134.2%
11/02/2026
Andrew Tsai
Jefferies
Buy
Reiterated
$305.00
+130.4%
11/02/2026
Joseph Thome
TD Cowen
Buy
Maintained
$135.00
+2%
11/02/2026
David Amsellem
Piper Sandler
Buy
Maintained
$235.00
+77.5%
11/02/2026
Matthew Hershenhorn
Oppenheimer
Buy
Maintained
$280.00
+111.5%
10/29/2026
Unknown Analyst
UBS
Buy
Maintained
$256.00
+93.4%
10/15/2026
Ami Fadia
Needham
Buy
Reiterated
$268.00
+102.5%
10/15/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$310.00
+134.2%
10/12/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$290.00
+119.1%
09/25/2026
Srikripa Devarakonda
Truist Financial
Buy
Initiated
$285.00
+115.3%
09/23/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/10/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$310.00
+134.2%
07/20/2026
Unknown Analyst
Jefferies
Buy
Maintained
$245.00
+85.1%
04/09/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
02/24/2026
Rudy Li
Wolfe Research
Buy
Initiated
$230.00
+73.8%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
196.00M
191.20M
218.38M
259.69M
Cost of goods sold
12.33M
14.72M
13.56M
17.80M
Cost of revenue
12.33M
14.72M
13.56M
17.80M
Research and development expenses
48.79M
52.68M
46.23M
50.62M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
169.30M
185.00M
208.14M
203.11M
Operating expense
219.70M
239.24M
255.95M
255.34M
Total operating expenses
232.02M
253.97M
269.52M
273.14M
Operating income
-36.02M
-62.77M
-51.14M
-13.45M
Other non operating income
-
-
-
-
EBT including unusual items
-28.13M
-64.54M
-51.19M
-12.79M
EBT excluding unusual items
-37.20M
-63.95M
-52.68M
-15.17M
Income tax expense
430.00K
-
128.00K
88.00K
Effective tax rate
-1.53%
-
-0.25%
-0.69%
Other operating expenses
-
-
-
-
Net income
-28.56M
-64.54M
-51.31M
-12.88M
Net profit margin
-14.57%
-33.76%
-23.50%
-4.96%
Earnings per share
-0.56
-1.26
-0.99
-0.25
Interest and investment income
2.04M
1.91M
1.66M
1.69M
Interest expense
-3.21M
-3.09M
-3.20M
-3.42M
Net interest expenses
-1.17M
-1.18M
-1.54M
-1.72M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.75M
-60.40M
-48.26M
-10.39M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps